Abcam, ab180707, Anti-UGT1A9 antibody

Size: 100µL
Rabbit Polyclonal UGT1A9 antibody. Suitable for WB, ICC/IF and reacts with Human, Mouse samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 1-250.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human,
Applications:WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 1-250. The exact immunogen used to generate this antibody is proprietary information.O60656

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.3Preservative: 0.02% Sodium azideConstituents: PBS, 50% Glycerol (glycerin, glycerine), Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UGT1A9 also known as UDP-glucuronosyltransferase 1-9 mechanistically catalyzes the glucuronidation of a variety of substrates including pharmaceuticals endogenous compounds and xenobiotics. It belongs to the UGT1A family with an approximate mass of 56 kDa. UGT1A9 is mainly expressed in the liver but it also shows expression in other tissues like the kidney and the small intestine. The enzyme plays an important role in increasing the solubility of drugs aiding their excretion from the body.
Biological function summary
UGT1A9 is involved in phase II metabolism contributing to the detoxification processes within the liver. It functions by adding glucuronic acid to lipophilic molecules making them more water-soluble. This glucuronidation process is essential for the clearance of bilirubin steroids and various drugs. UGT1A9 exists as a part of a larger enzyme complex that includes other UGT1A family members. Together these enzymes regulate action and metabolism of diverse physiological substances.
Pathways
The UGT1A9 enzyme contributes significantly to the glucuronidation pathway and assists in the drug metabolism pathway. It shares functional relationships with other UGT1A enzymes like UGT1A1 particularly in the metabolism of bilirubin. In the drug metabolism pathway UGT1A9 interacts with cytochrome P450 enzymes playing an important role in the reduction of drug toxicity and facilitation of drug clearance.
UGT1A9 has been linked to Gilbert's syndrome and drug-induced hepatotoxicity. Mutations or polymorphisms in the UGT1A9 gene can lead to impaired ability of the enzyme to glucuronidate bilirubin potentially contributing to hyperbilirubinemia in Gilbert's syndrome. UGT1A9 also interacts with proteins such as UGT1A1 in the context of drug-induced liver injury affecting the metabolism of certain therapeutic drugs leading to potential toxic buildup.